Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Cara Therapeutics
(NQ:
CARA
)
0.3600
+0.0085 (+2.42%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Cara Therapeutics
< Previous
1
2
Next >
Cara Therapeutics Announces Exploration of Strategic Alternatives
July 11, 2024
Piper Sandler & Co. to act as financial advisor
From
Cara Therapeutics, Inc.
Via
GlobeNewswire
Cara Therapeutics Announces Outcome of Part A of KOURAGE-1 Study Evaluating Oral Difelikefalin in Notalgia Paresthetica
June 12, 2024
From
Cara Therapeutics, Inc.
Via
GlobeNewswire
Cara Therapeutics Reports First Quarter 2024 Financial Results
May 13, 2024
Topline efficacy and safety results from KOURAGE 1 Part A portion of notalgia paresthetica (NP) pivotal program now expected by the end of 2Q24
From
Cara Therapeutics, Inc.
Via
GlobeNewswire
Cara Therapeutics to Announce First Quarter 2024 Financial Results on May 13, 2024
May 06, 2024
From
Cara Therapeutics, Inc.
Via
GlobeNewswire
Cara Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference
April 02, 2024
From
Cara Therapeutics, Inc.
Via
GlobeNewswire
Cara Therapeutics to Host Notalgia Paresthetica (NP) Virtual KOL Event on Wednesday, March 27, 2024
March 07, 2024
From
Cara Therapeutics, Inc.
Via
GlobeNewswire
Cara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
March 04, 2024
From
Cara Therapeutics, Inc.
Via
GlobeNewswire
Cara Therapeutics to Announce Fourth Quarter and Full Year 2023 Financial Results on March 4, 2024
February 12, 2024
From
Cara Therapeutics, Inc.
Via
GlobeNewswire
Cara Therapeutics Prioritizes Late-Stage Notalgia Paresthetica Program and Extends Cash Runway into 2026
January 22, 2024
From
Cara Therapeutics, Inc.
Via
GlobeNewswire
Cara Therapeutics Announces Outcome from Dose-Finding Part A of KIND 1 Study Evaluating Oral Difelikefalin for Moderate-to-Severe Pruritus in Patients with Atopic Dermatitis
December 18, 2023
From
Cara Therapeutics, Inc.
Via
GlobeNewswire
Cara Therapeutics Reports Third Quarter 2023 Financial Results
November 13, 2023
From
Cara Therapeutics, Inc.
Via
GlobeNewswire
Cara Therapeutics Announces up to $40.0 Million Non-Dilutive Financing Agreement with HealthCare Royalty
November 02, 2023
From
Cara Therapeutics, Inc.
Via
GlobeNewswire
Cara Therapeutics to Announce Third Quarter 2023 Financial Results on November 13, 2023
October 23, 2023
From
Cara Therapeutics, Inc.
Via
GlobeNewswire
Cara Therapeutics Announces Approval of KORSUVA® IV Injection Syringe in Japan for the Treatment of Pruritus in Hemodialysis Patients
September 25, 2023
Approval triggers $1.5 million milestone payment to Cara
From
Cara Therapeutics, Inc.
Via
GlobeNewswire
Cara Therapeutics Inc. (NASDAQ: CARA) Leading the Way in Friday Trading Based on Percentage Gain
September 15, 2023
Via
Investor Brand Network
Cara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 05, 2023
From
Cara Therapeutics, Inc.
Via
GlobeNewswire
Cara Therapeutics Reports Second Quarter 2023 Financial Results
August 07, 2023
From
Cara Therapeutics, Inc.
Via
GlobeNewswire
Cara Therapeutics Appoints Helen M. Boudreau to Board of Directors
August 03, 2023
From
Cara Therapeutics, Inc.
Via
GlobeNewswire
Cara Therapeutics to Present at the Canaccord Genuity 43rd Annual Growth Conference
August 02, 2023
From
Cara Therapeutics, Inc.
Via
GlobeNewswire
Cara Therapeutics to Announce Second Quarter 2023 Financial Results on August 7, 2023
July 24, 2023
From
Cara Therapeutics, Inc.
Via
GlobeNewswire
Cara Therapeutics to Present at the Jefferies Healthcare Conference
June 01, 2023
From
Cara Therapeutics, Inc.
Via
GlobeNewswire
Kapruvia® (difelikefalin) recommended by England’s NICE for the treatment of adults with moderate-to-severe CKD-associated pruritus
May 18, 2023
Recommendation will enable eligible patients in England, Wales and Northern Ireland to access the first licensed treatment for moderate-to-severe chronic kidney disease (CKD)-associated pruritus in...
From
Cara Therapeutics, Inc.
Via
GlobeNewswire
Cara Therapeutics Reports First Quarter 2023 Financial Results
May 15, 2023
From
Cara Therapeutics, Inc.
Via
GlobeNewswire
Cara Therapeutics to Announce First Quarter 2023 Financial Results on May 15, 2023
May 01, 2023
From
Cara Therapeutics, Inc.
Via
GlobeNewswire
Cara Therapeutics Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference
April 10, 2023
From
Cara Therapeutics, Inc.
Via
GlobeNewswire
Cara Therapeutics Releases Inaugural Environmental, Social, and Governance Report
March 14, 2023
From
Cara Therapeutics, Inc.
Via
GlobeNewswire
Cara Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results
March 06, 2023
From
Cara Therapeutics, Inc.
Via
GlobeNewswire
Cara Therapeutics to Announce Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023
February 21, 2023
From
Cara Therapeutics, Inc.
Via
GlobeNewswire
Cara Therapeutics Announces Results from the KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Notalgia Paresthetica Published in the New England Journal of Medicine
February 08, 2023
Publication underscores the importance of data in underrecognized neuropathic itch disorder which lacks an approved treatment
From
Cara Therapeutics, Inc.
Via
GlobeNewswire
Cara Therapeutics to Host Capital Markets Day on Thursday, February 16, 2023
January 17, 2023
From
Cara Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.